

Clinical trials of taspoglutide

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
taspoglutide 10mg once weekly vs placebo			
Nauck 10 once weekly vs PBO , 2009 [NCT00423501] n=257/49 follow-up: 12 weeks	taspoglutide, either 5, 10, or 20 mg once weekly or 10 or 20 mg once every 2 weeks for 8 weeks versus placebo	patients with type 2 diabetes inadequately controlled with metformin	Parallel groups double-blind
taspoglutide 20mg once every 2 weeks vs placebo			
Nauck 20 every 2 weeks vs PBO , 2009 n=NA	-	-	
taspoglutide 20mg once weekly vs placebo			
Nauck 20 once weekly vs PBO , 2009 n=NA	-	-	
taspoglutide vs placebo			
BC20750 ongoing [NCT00744926] n=NA follow-up:	taspoglutide 10mg sc once weekly, or taspoglutide 20mg sc once weekly (after 4 weeks of taspoglutide 10mg sc once weekly) versus placebo	patients with type 2 diabetes mellitus inadequately controlled with diet and exercise	double-blind USA
BC20963 ongoing [NCT00744367] n=NA follow-up: 24 weeks	taspoglutide 10mg once weekly, taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) versus placebo in addition to their continued stable metformin plus pioglitazone treatment	patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone	double-blind USA

continued...

Trial	Treatments	Patients	Trials design and methods
BC21713 (vs placebo) <i>ongoing</i> [NCT00754988] n=NA follow-up:	taspoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly), versus placebo or sitagliptin 100mg once daily in addition to their continued prestudy metformin treatment	patients with type 2 diabetes mellitus inadequately controlled with metformin	parallel groups double-blind USA
BP21572 <i>ongoing</i> [NCT00809705] n=NA follow-up: 12 weeks	10mg Taspoglutide sc weekly for 12 weeks b)10mg Taspoglutide sc weekly for 4 weeks followed by 20mg Taspoglutide sc weekly for 8 weeks versus placebo	patients with type 2 diabetes	double-blind germany
NCT01018173 <i>ongoing</i> [NCT01018173] n=NA	-	-	
taspoglutide vs placebo (add on MET)			
Ratner (20mg once weekly) , 2010 [NCT00460941] n=97/32 follow-up: 8 weeks (+4wk)	taspoglutide s.c. 20mg once weekly for 8 weeks versus placebo s.c. once weekly on top metformin	subjects with Type 2 diabetes inadequately controlled on metformin alone	Parallel groups double-blind Australia, France, Germany, Mexico, Peru, USA
BC22092 <i>ongoing</i> [NCT00823992] n=NA follow-up:	taspoglutide (10mg sc once weekly for 4 weeks followed by 20mg once weekly) in addition to their prescribed, pre-existing metformin therapy versus placebo	obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy	parallel groups double-blind USA
taspoglutide vs placebo add on standard treatment			
NC25113 <i>ongoing</i> [NCT01018173] n=NA follow-up:	taspoglutide subcutaneously (sc) 10mg weekly for 4 weeks followed by 20mg sc weekly in addition to background anti-hyperglycemic medication and standard of care treatment for cardiovascular disease versus placebo	-	parallel groups double-blind USA
taspoglutide vs exenatide			

continued...

Trial	Treatments	Patients	Trials design and methods
BC21625 <i>ongoing</i> [NCT00717457] n=NA follow-up:	taspoglutide versus exenatide	patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both	parallel groups open USA
taspoglutide vs insulin glargine			
ZC22565 <i>ongoing</i> [NCT01051011] n=NA follow-up:	taspoglutide 10mg subcutaneously (sc) weekly, or taspoglutide 10mg sc weekly for 4 weeks followed by 20mg sc weekly versus insulin glargine at an initial dose of 10 international units sc daily	insulin-naive patients with type 2 diabetes mellitus inadequately controlled on merformin and sulfonylurea combination therapy	parallel groups open China
taspoglutide vs insulin glargine (add on MET)			
BC20965 <i>ongoing</i> [NCT00755287] n=NA follow-up: 2 years	taspoglutide (10 mg once weekly, or 10mg once weekly for 4 weeks followed by 20mg once weekly) versus insulin glargine (starting dose 10 IU/day) in addition to continued prestudy metformin treatment	patients with insulin-naive type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea combination therapy	open USA
taspoglutide vs pioglitazone			
BC21893 <i>ongoing</i> [NCT00909597] n=NA follow-up: 24 months	taspoglutide 10mg sc weekly, or taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly versus pioglitazone 45mg/day po after 4 weeks of pioglitazone 30mg/day po	patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy	parallel groups double-blind USA

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in Patients inadequately controlled on MET+SU therapy at <http://www.trialresultscenter.org/go-Q510>
- antidiabetic drugs for diabetes type 2 in patients with insufficient glycaemic control with bitherapy at <http://www.trialresultscenter.org/go-Q511>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>

- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at <http://www.trialresultscenter.org/go-Q513>
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>

References

Nauck 10 once weekly vs PBO, 2009:

Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R, Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. *Diabetes Care* 2009;32:1237-43. [19366970] [10.2337/dc08-1961](https://doi.org/10.2337/dc08-1961)

Nauck 20 every 2 weeks vs PBO, 2009:

Nauck 20 once weekly vs PBO, 2009:

BC20750, 0:

ongoing trial NCT00744926

BC20963, 0:

ongoing trial NCT00744367

BC21713 (vs placebo), 0:

ongoing trial NCT00754988

BP21572, 0:

ongoing trial NCT00809705

NCT01018173, :

ongoing trial NCT01018173

Ratner (20mg once weekly), 2010:

Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R, Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. *Diabet Med* 2010;27:556-62. [20536952] [10.1111/j.1464-5491.2010.02990.x](https://doi.org/10.1111/j.1464-5491.2010.02990.x)

BC22092, 0:

ongoing trial NCT00823992

NC25113, 0:

ongoing trial NCT01018173

BC21625, 0:

ongoing trial NCT00717457

ZC22565, 0:

ongoing trial NCT01051011

BC20965, 0:

ongoing trial NCT00755287

BC21893, 0:

ongoing trial NCT00909597

Entry terms: taspoglutide,